Anne Johnson named CFO of atai Life Sciences; Stephen Bardin departs

ATAI Life Sciences N.V.

Stephen Bardin steps down as CFO effective Feb 6, 2024; will advise through March 31, 2024.
Anne Johnson, previously Interim CFO and Chief Accounting Officer, appointed CFO.
Bardin receives severance: 9 months base salary, COBRA, $149,600 bonus, $30,462 parental leave.
Johnson brings ~20 years biopharma experience from Aruvant, Chimerix, PPD, and Xanodyne.
Separation agreement includes release of claims and non-disclosure covenants.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anne Johnson

Chief Financial Officer

ATAI Life Sciences N.V.

Effective: 2024-02-06
Filed: February 6, 2024, 6:59 PM ET

Effective February 6, 2024, Ms. Johnson was appointed the Company’s Chief Financial Officer, succeeding Mr. Bardin.

Departed

Stephen Bardin

Chief Financial Officer

ATAI Life Sciences N.V.

Effective: 2024-02-06
Successor: Anne Johnson
Filed: February 6, 2024, 6:59 PM ET

on February 1, 2024, the Company and Mr. Bardin reached an agreement regarding Mr. Bardin’s departure from his position as the Company’s Chief Financial Officer (the “ Separation Agreement ”), effective as of February 6, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Anne Johnson was appointed as Chief Financial Officer at ATAI Life Sciences N.V..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective February 6, 2024, Ms. Johnson was appointed the Company’s Chief Financial Officer, succeeding Mr. Bardin.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Stephen Bardin departed as Chief Financial Officer at ATAI Life Sciences N.V..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

on February 1, 2024, the Company and Mr. Bardin reached an agreement regarding Mr. Bardin’s departure from his position as the Company’s Chief Financial Officer (the “ Separation Agreement ”), effective as of February 6, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001140361-24-005889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.